Year: 2022

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal year ended September 30, 2022. “This is an exciting time in neuroscience and rare disease drug development and we remain on track for the readout of the placebo-controlled ANAVEX®2-73 Phase 2b/3 Alzheimer’s disease clinical trial, a condition of significant unmet need and economic burden for which there are only limited approved pharmacological treatment...

TORONTO, Nov. 28, 2022 (GLOBE NEWSWIRE) — Denarius Metals Corp. (“Denarius Metals” or “the Company”) (TSXV: DSLV; OTCQB: DNRSF) announced today that it has filed its unaudited interim condensed consolidated financial statements and accompanying management’s discussion and analysis (MD&A) for the three and nine months ended September 30, 2022. These documents can be found on its website at www.denariusmetals.com and by reviewing its profile on SEDAR at www.sedar.com. All financial figures contained herein are expressed in U.S. dollars unless otherwise noted. Commenting on the third quarter and first nine months 2022 results, Serafino Iacono, Chairman and Chief Executive Officer of Denarius Metals, stated, “We are continuing to execute our strategy to create a producer of copper, zinc, lead, silver and gold from high-grade projects...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, Nov. 28, 2022 (GLOBE NEWSWIRE) — Hempsana Holdings Ltd. (the “Company” or “Hempsana”) today announced three and nine months financial results for the period ended September 30, 2022. Randy Ko, Hempsana’s CEO commented: “Our team remains focused on leading the market in the manufacturing and distribution of rare cannabinoids to support product development cycles with many of the major consumer brand leaders in Canada. Our management team continues to keep their ears to the ground on consumer data driven insights, innovation and brand development as we continue to expand on our strategic partnership program to bring unique products to market....

A total of 8,402 hotels or 797,489 hotel rooms in operation as of September 30, 2022. Hotel turnover1 increased 24.4% year-over-year to RMB15.2 billion in the third quarter of 2022. Excluding Steigenberger Hotels AG and its subsidiaries (“DH”, or “Legacy-DH”), hotel turnover increased 21.6% year-over-year in the third quarter of 2022. Revenue increased 16.2% year-over-year to RMB4.1 billion (US$575 million)2 in the third quarter of 2022, in line with the revenue guidance previously announced of a 13% to 17% increase compared to the third quarter of 2021. Revenue from the Legacy-Huazhu segment in the third quarter of 2022 increased 7.7% year-over-year, in line with revenue guidance previously announced of a 5% to 9% increase. Net loss attributable to H World Group Limited was RMB717 million (US$101 million) in the third quarter of 2022,...